statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML

Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML PR Newswire HOUSTON, July 10, 2024 HOUSTON, July 10...

Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial

Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial PR Newswire HOUSTON...

Moleculin to Present at the Virtual Investor Pitch Conference

Moleculin to Present at the Virtual Investor Pitch Conference Moleculin to Present at the Virtual Investor Pitch Conference PR Newswire HOUSTON, June 12, 2024 Live video webcast on Tuesday, June 18th...

Moleculin to Participate in the Virtual Investor Lunch Break Series

Moleculin to Participate in the Virtual Investor Lunch Break Series Moleculin to Participate in the Virtual Investor Lunch Break Series PR Newswire HOUSTON, June 5, 2024 Live webcast with Walter...

Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress

Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress Moleculin Abstract Accepted for Poster Presentation at the European Hematology...

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06) Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical...

Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update

Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update PR Newswire HOUSTON, May 13...

Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin

Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for...

Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast

Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host...

Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data

Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant...

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. It engages in the business of growing a pipeline including phase 2 clinical programs for hard-to-treat cancers and viruses. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.

Volume	9,488.00
52-Wk High	$15.75
52-Wk Low	$3.22

MBRX Moleculin Biotech Inc

About

Feed

News

Sentiment

Fundamentals